Femasys to Exhibit at ASRM 2024 and Participate in the Congress’ KEEPR Education Program
Femasys Inc. (Nasdaq: FEMY) announces its participation in the American Society of Reproductive Medicine's (ASRM) 2024 Scientific Congress and Expo from October 19-23 in Denver, Colorado. The company will showcase its products at booth #243, with FemaSeed® and FemVue® featured in ASRM's KEEPR program for residents on October 23.
Notably, Femasys' VP of Education and Global Training, Andrew Young, has been elected chairman of the ASRM Corporate Member Council for a one-year term. This council facilitates dialogue between ASRM officers, directors, and corporate members to drive education and innovation in reproductive medicine.
CEO Kathy Lee-Sepsick emphasized the importance of ASRM's event for demonstrating Femasys' product value to healthcare practitioners and thought leaders, as well as engaging with young physicians through product training.
Femasys Inc. (Nasdaq: FEMY) annuncia la sua partecipazione al Congresso Scientifico e Expo 2024 dell'American Society of Reproductive Medicine (ASRM) che si terrà dal 19 al 23 ottobre a Denver, Colorado. L'azienda presenterà i suoi prodotti allo stand n. 243, con FemaSeed® e FemVue® inclusi nel programma KEEPR dell'ASRM per i residenti il 23 ottobre.
È significativo che il VP dell'Istruzione e della Formazione Globale di Femasys, Andrew Young, sia stato eletto presidente del Consiglio dei Membri Aziendali dell'ASRM per un mandato di un anno. Questo consiglio facilita il dialogo tra i funzionari, i direttori dell'ASRM e i membri aziendali per promuovere l'istruzione e l'innovazione nella medicina riproduttiva.
La CEO Kathy Lee-Sepsick ha sottolineato l'importanza dell'evento dell'ASRM per dimostrare il valore dei prodotti Femasys agli operatori sanitari e ai leader del pensiero, nonché per coinvolgere i giovani medici attraverso la formazione sui prodotti.
Femasys Inc. (Nasdaq: FEMY) anuncia su participación en el Congreso Científico y Expo 2024 de la Sociedad Americana de Medicina Reproductiva (ASRM) del 19 al 23 de octubre en Denver, Colorado. La compañía exhibirá sus productos en el stand n.º 243, con FemaSeed® y FemVue® destacados en el programa KEEPR de la ASRM para residentes el 23 de octubre.
Es notable que el vicepresidente de Educación y Capacitación Global de Femasys, Andrew Young, ha sido elegido presidente del Consejo de Miembros Corporativos de la ASRM por un período de un año. Este consejo facilita el diálogo entre los oficiales y directores de la ASRM y los miembros corporativos para impulsar la educación y la innovación en la medicina reproductiva.
La CEO Kathy Lee-Sepsick enfatizó la importancia del evento de la ASRM para demostrar el valor de los productos de Femasys a los profesionales de la salud y líderes de opinión, así como para involucrar a médicos jóvenes a través de la capacitación en productos.
Femasys Inc. (Nasdaq: FEMY)는 10월 19일부터 23일까지 콜로라도주 덴버에서 열리는 2024 미국 생식 의학회(ASRM) 과학 회의 및 박람회에 참여한다고 발표했습니다. 회사는 부스 번호 243에서 제품을 전시하며, FemaSeed®와 FemVue®는 10월 23일 ASRM의 KEEPR 프로그램에서 레지던트를 위해 소개됩니다.
특히 Femasys의 교육 및 글로벌 훈련 부사장인 Andrew Young가 ASRM 기업 회원 위원회의 의장으로 1년 임기 동안 선출되었습니다. 이 위원회는 ASRM의 임원, 이사 및 기업 회원 간의 대화를 촉진하여 생식 의학의 교육과 혁신을 추진합니다.
CEO Kathy Lee-Sepsick는 ASRM 행사가 Femasys의 제품 가치를 의료 전문가와 사고 리더에게 보여주고, 젊은 의사들과 제품 교육을 통해 소통하는 데 중요하다고 강조했습니다.
Femasys Inc. (Nasdaq: FEMY) annonce sa participation au Congrès scientifique et à l'Expo 2024 de l'American Society of Reproductive Medicine (ASRM) qui se déroulera du 19 au 23 octobre à Denver, Colorado. L'entreprise présentera ses produits au stand n°243, avec FemaSeed® et FemVue® mis en avant dans le programme KEEPR de l'ASRM pour les résidents le 23 octobre.
À noter que le VP Éducation et Formation mondiale de Femasys, Andrew Young, a été élu président du Conseil des membres corporatifs de l'ASRM pour un mandat d'un an. Ce conseil facilite le dialogue entre les responsables et directeurs de l'ASRM et les membres corporatifs afin de promouvoir l'éducation et l'innovation dans le domaine de la médecine reproductive.
La PDG Kathy Lee-Sepsick a souligné l'importance de l'événement de l'ASRM pour démontrer la valeur des produits de Femasys aux professionnels de la santé et aux leaders d'opinion, ainsi que pour engager des jeunes médecins à travers des formations sur les produits.
Femasys Inc. (Nasdaq: FEMY) gibt seine Teilnahme am Wissenschaftlichen Kongress und der Expo 2024 der American Society of Reproductive Medicine (ASRM) vom 19. bis 23. Oktober in Denver, Colorado, bekannt. Das Unternehmen wird seine Produkte am Stand Nr. 243 präsentieren, wobei FemaSeed® und FemVue® am 23. Oktober im KEEPR-Programm der ASRM für residenten vorgestellt werden.
Bemerkenswert ist, dass Femasys' VP für Bildung und globale Ausbildung, Andrew Young, für eine einjährige Amtszeit zum Vorsitzenden des ASRM Corporate Member Council gewählt wurde. Dieser Rat erleichtert den Dialog zwischen den ASRM-Beamten, -Direktoren und den Unternehmensmitgliedern, um Bildung und Innovation in der reproduktiven Medizin voranzutreiben.
CEO Kathy Lee-Sepsick betonte die Bedeutung der ASRM-Veranstaltung, um den Wert der Femasys-Produkte für Gesundheitsdienstleister und Vordenker zu demonstrieren sowie mit jungen Ärzten durch Produktschulungen in Kontakt zu treten.
- Femasys products FemaSeed® and FemVue® featured in ASRM's KEEPR program for resident education
- VP of Education and Global Training elected chairman of ASRM Corporate Member Council
- Opportunity to showcase products to healthcare practitioners and thought leaders at ASRM event
- None.
Company’s VP of Education and Global Training Named Chairman of ASRM Corporate Member Council
ATLANTA, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, announces that the Company will be exhibiting at the American Society of Reproductive Medicine’s (ASRM) 2024 Scientific Congress and Expo, being held October 19-23 in Denver, Colorado. The Company will be showcasing its solutions at booth #243.
Femasys’ FemaSeed® and FemVue® products will be featured in ASRM’s Knowledge through Engagement and Education Program for Residents (KEEPR) program. The in-person resident program, being held October 23, will offer exclusive evidence-based and bias-free learning for residents. Through interactive workshops, skill-building activities, and advanced independent study, residents will explore important and trending topics with experts, including working with products that impact and preserve reproduction.
Additionally, Femasys VP of Education and Global Training, Andrew Young was elected chairman of the ASRM Corporate Member Council, as voted by peers in reproductive medicine and corporate memberships. The Corporate Member Council is a partnership between ASRM officers, directors, and corporate members and is designed to facilitate open and ongoing dialogue between the two to drive education and innovation, which will serve to enhance the practice of reproductive medicine. Young will begin his one-year term at the close of the ASRM event. Femasys’ CEO, Kathy Lee-Sepsick is also a member of the Council.
Lee-Sepsick commented, “The ASRM is a key advocate for reproductive medicine and its annual event an important venue for us to demonstrate the value of our products to healthcare practitioners and thought leaders in attendance. We are grateful that the organizers have recognized that FemaSeed and FemVue represent part of the future of reproductive medicine, and we are eager to engage with young physicians as they learn about the advantages and are trained on the use of our products. We are particularly proud of Andrew Young for being elected as chair of the ASRM Corporate Member Council and look forward to our continued collaboration with ASRM as we advance our U.S. commercialization efforts for FemaSeed and FemVue.”
To learn more about ASRM 2024, visit the organization’s website.
About Femasys
Femasys is a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic solutions, including a lead revolutionary product candidate and FDA-cleared products. FemaSeed® Intratubal Insemination, an innovative infertility treatment designed to deliver sperm directly where conception occurs, is FDA-cleared and has received regulatory approval in Canada and Europe. FemBloc® permanent birth control in late-stage clinical development is the first and only non-surgical, in-office, permanent birth control method intended to be a safer option for women at substantially less cost than the long-standing surgical alternative. The Company has developed diagnostic products that are complementary for which it has achieved regulatory approvals to market in the U.S., Canada, Europe, and other ex-U.S. territories, and which are commercial-ready due to its in-house manufacturing capabilities. Its diagnostic products include FemVue® and FemVue® Mini for fallopian tube assessment by ultrasound, which can be used in conjunction with FemCath®, an intrauterine catheter for selective fallopian tube evaluation, and FemCerv®, an endocervical tissue sampler for cervical cancer diagnosis. Learn more at www.femasys.com, or follow us on X, Facebook and LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements that are subject to substantial risks and uncertainties. Forward-looking statements can be identified by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “pending,” “intend,” “believe,” “suggests,” “potential,” “hope,” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions, many of which are beyond our control, difficult to predict and could cause actual results to differ materially from what we expect. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, among others: our ability to develop and advance our current product candidates and programs into, and successfully initiate, enroll and complete, clinical trials; the ability of our clinical trials to demonstrate safety and effectiveness of our product candidates and other positive results; estimates regarding the total addressable market for our products and product candidates; our ability to commercialize our products and product candidates, or the effect of delays in commercializing our products, including FemaSeed; our business model and strategic plans for our products, technologies and business, including our implementation thereof; and those other risks and uncertainties described in the section titled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2023, and other reports as filed with the SEC. Forward-looking statements contained in this press release are made as of this date, and Femasys undertakes no duty to update such information except as required under applicable law.
Contacts:
Investors:
Matt Blazei
IR@femasys.com
Media:
Kati Waldenburg
Media@femasys.com
FAQ
When and where is Femasys (FEMY) exhibiting at ASRM 2024?
Which Femasys (FEMY) products will be featured in ASRM's KEEPR program?
Who was elected chairman of the ASRM Corporate Member Council from Femasys (FEMY)?
